Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Geron Corp. -- Ignore unavailable to you. Want to Upgrade?

To: Pullin-GS who wrote (1295)	11/7/1998 4:23:00 PM
From: Rocky Reid	Respond to of 3576

Has Barrons trashed this dog yet? I'm short @ $20 1/2 as of Friday. We should see GERN fall back down to the $12 level real soon. The momentum was already dying late afternoon. On Monday, watch for all of the competitors to come crawling out of the woodwork saying they are farther along in their stem cell research than this tiny outfit. Happens almost every time.

To: Pullin-GS who wrote (1295)	11/7/1998 4:24:00 PM
From: Impristine	Respond to of 3576

I think this guy went Long on GERN Friday.... exchange2000.com

To: Pullin-GS who wrote (1295)	11/8/1998 12:19:00 PM
From: Pullin-GS	Respond to of 3576

Excerpt from briefing.com (January)........... Reads like a broken record. BTW this made TIME magazing, ABC news, CNBC, etc. GERON CORP (GERN) 12 7/16 +2 7/16. GERN shares rose 24% before being halted on news. The news: the company and the University of Texas Southwestern Medical Center at Dallas reported today the successful extension of the life-span of normal human cells using the enzyme telomerase. In a paper published in the journal Science, January 16, 1998, scientists explain that the introduction of an active telomerase gene into normal mortal cells resulted in the lengthening of telomeres and a marked increase in the life-span of the cells, making the cell potentially immortal. "The paper is a monumental advance in the understanding of the molecular genetics of aging... will likely have many important applications in the future of medicine and cell engineering..." Sounds great. But what does in mean to me as a potential investor. Well, when the stock finally reopens, the shares will more than likely spurt several points higher. However, history tells us (particurly the history of GERN), that this issue will come tumbling down on the next weak day in the market. Yea, GERN is an old favorite of ours. The last time we recommended that investors consider a short of these shares was August 15, when the stock leapt more than 150% on news the company identified a protein key to the uncontrolled growth of cancer cells. If you had shorted then, you would have made as much as 50% on your money. Regards...